BACKGROUND: Peripheral neuropathy is a major dose-limiting toxicity of chemotherapy, especially after multiple courses of paclitaxel. The development of paclitaxel-induced neuropathy is associated with the activation of microglia followed by the activation and proliferation of astrocytes, and the expression and release of proinflammatory cytokines in the spinal dorsal horn. Cannabinoid type 2 (CB 2 ) receptors are expressed in the microglia in neurodegenerative disease models. METHODS: To explore the potential of CB 2 agonists for preventing paclitaxel-induced neuropathy, we designed and synthesized a novel CB 2 -selective agonist, namely, MDA7. The effect of MDA7 in preventing paclitaxel-induced allodynia was assessed in rats and in CB 2 ϩ/ϩ and CB 2 Ϫ/Ϫ mice. We hypothesized that the CB 2 receptor functions in a negative-feedback loop and that early MDA7 administration can blunt the neuroinflammatory response to paclitaxel and prevent mechanical allodynia through interference with specific signaling pathways. RESULTS: We found that MDA7 prevents paclitaxel-induced mechanical allodynia in rats and mice in a dose-and time-dependent manner without compromising paclitaxel's antineoplastic effect. MDA7's neuroprotective effect was absent in CB 2 Ϫ/Ϫ mice and was blocked by CB 2 antagonists, suggesting that MDA7's action directly involves CB 2 receptor activation. MDA7 treatment was found to interfere with early events in the paclitaxel-induced neuroinflammatory response as evidenced by relatively reduced toll-like receptor and CB 2 expression in the lumbar spinal cord, reduced levels of extracellular signal-regulated kinase 1/2 activity, reduced numbers of activated microglia and astrocytes, and reduced secretion of proinflammatory mediators in vivo and in in vitro models. CONCLUSIONS: Our findings suggest an innovative therapeutic approach to prevent chemotherapyinduced neuropathy and may permit more aggressive use of active chemotherapeutic regimens with reduced long-term sequelae.
N europathic pain, characterized by a reduced nociceptive threshold, persists in the absence of a stimulus and is refractory to traditional analgesics. Cancer patients are at increased risk of neuropathic pain caused by radiotherapy or a variety of chemotherapeutic drugs, including paclitaxel. Paclitaxel has significant clinical activity and is frequently administered in the management of breast, lung, and ovarian cancers 1 ; however, its optimal use is limited by its adverse effects, including myelosuppression and peripheral neuropathy. The myelosuppressive side effects have been partially addressed by the use of hematopoietic growth factors (e.g., granulocyte and granulocyte-macrophage colony-stimulating factors) before or after treatment and by altering paclitaxel doses and schedules. 2 Unfortunately, sensory peripheral neuropathy remains a significant long-term problem that limits the amount of paclitaxel treatment that can be administered. [3] [4] [5] Severe peripheral neuropathy (National Cancer Institute Common Toxicity Criteria grade 3 or 4) is dose dependent and may affect up to 88% of patients receiving paclitaxelbased chemotherapy. 6 In many patients, neuropathic pain persists throughout life and negatively affects physical, emotional, and social quality of life. 7 There is currently no effective symptomatic treatment for paclitaxel-induced neuropathy. Opioids, gabapentin, amitriptyline, and medicinal cannabis preparations have been tried and shown to be ineffective. 8 -10 Because treatments for intact neuropathic pain have limitations, there is increasing interest in developing preventive strategies. Several neuroprotective drugs have been tested in animal models and clinical trials for their ability to prevent chemotherapy-associated neuropathy, but these studies have yielded conflicting results.
The pathophysiologic underpinnings of peripheral neuropathy are not well understood. Because taxanes cause microtubule stabilization, it has been proposed that taxaneinduced peripheral neuropathy might be a direct consequence of microtubular damage. However, peripheral neuropathy also occurs with use of various other chemotherapeutic drugs that have different mechanisms of action, including vinca alkaloids (which destabilize microtubules), cisplatin, oxaliplatin, carboplatin, bortezomib, and thalidomide. 17 Thus, it is hypothesized that peripheral neuropathy is a downstream event that can be initiated by any of a variety of upstream mechanisms.
The upstream initiators of peripheral neuropathy are not well understood; however, the process has the hallmarks of a neuroinflammatory response after innate immune system activation. For example, in the setting of mechanical allodynia associated with nerve transection, 18, 19 toll-like receptors 2 and 4 (TLR2 and TLR4) found on microglia seem to trigger glial activation, initiating proinflammatory and signal transduction pathways 20, 21 that lead to the production of proinflammatory cytokines. Similarly, in the setting of paclitaxel treatment, a TLR4-mediated initiating signal 22, 23 leads to activation of microglia, activation and proliferation of astrocytes, 24 -27 and expression and release of inflammatory cytokines. 28, 29 Established mechanical allodynia can be reversed by intrathecally delivered TLR4 receptor antagonists, 30 which prevent transcription factor nuclear factor -light-chain-enhancer of activated B cells (NF-B) activation and tumor necrosis factor (TNF)-␣ overproduction in the spinal cord after sciatic nerve injury. 18 The endogenous cannabinoid system is a complex system consisting of 2 cannabinoid (CB) receptors (CB 1 , expressed primarily in the brain, and CB 2 , expressed primarily in the peripheral immune system 31 and in the central nervous system [CNS] 32 ), 7 endogenous endocannabinoid ligands (arachidonic acid derivatives) including anandamide (N-arachidonoylethanolamine) and 2-arachidonoylglycerol, 33 and several proteins responsible for the regulation of endocannabinoid metabolic pathways, such as monoacylglycerol lipase and fatty acid amide hydrolase. 34 CB 1 and CB 2 are 7 transmembrane, G protein-coupled receptors, and they share 44% overall identity. Both receptors mediate inhibition of adenylyl cyclases and stimulation of mitogen-activated protein kinases (MAPKs). Unlike CB 1 , CB 2 seems to poorly modulate calcium channels or inwardly rectifying potassium channels. 35 The endocannabinoid 2-arachidonoylglycerol was found to act as a full agonist (whereas anandamide acts as a weak partial agonist) toward CB 1 and CB 2 receptors. 36, 37 Inflammatory conditions such as Alzheimer disease 38, 39 or peripheral nerve injury 40, 41 increase the expression of CB 2 receptors in the CNS. CB 2 receptor agonists have been shown to attenuate allodynia in animal models of formalin intraplantar injection 42 and spinal nerve ligation. [42] [43] [44] Microglia express CB 2 mRNA in the spinal cord in the settings of neuropathic pain models, and this expression is colocalized with the activated microglia. 40 Although the physiologic role of CB 2 receptors in the neuropathic response is not well understood, they seem to have a crucial role in the negative regulation of central immune response observed with mechanical allodynia induced by sciatic nerve injury in mice. 45 For example, the manifestation of mechanical allodynia was more evident in CB 2 knockout mice than in their wild-type littermates, and mechanical allodynia was attenuated in transgenic mice overexpressing CB 2 receptors. 45 Similarly, in vitro CB 2 receptor stimulation suppresses microglial cell activation. 46 Synthetic ⌬ 9 -tetrahydrocannabinol analogues (e.g., Marinol [Bayer, Inc., Toronto, Ontario, Canada], Cesamet [Institute for Clinical Research, IKF, Berlin, Germany]) and medicinal cannabis preparations containing both ⌬ 9 -tetrahydrocannabinol and cannabidiol (e.g., Sativex, Cannador) have been tried clinically in patients with neuropathic pain. However, in all trials, these drugs failed to show efficacy compared with placebo, and their use resulted in a high incidence of psychotropic adverse effects. [47] [48] [49] [50] In contrast, CB 2 agonists are neuroprotective and are emerging as treatments for neuropathic pain. Moreover, they lack the psychotropic adverse effects that normally occur with CB 1 agonists. 42, 43, [51] [52] [53] To explore the role of CB 2 agonists in preventing neuropathic pain, we designed and synthesized 2 novel series of CB 2 agonists. 43,54 -56 We first assessed the absorption, distribution, metabolism, and excretion and toxicity (ADMETox) properties of one of our lead compounds, MDA7.
56
MDA7 was selected for animal studies because it did not show any ADME-Tox-related issues. We then demonstrated the efficacy of MDA7 in ameliorating allodynia induced by either nerve ligation or paclitaxel administration in rats. 43 Moreover, MDA7 caused no impairment of locomotor activities in rats. 43 We therefore tested the hypothesis that MDA7 could prevent paclitaxel-induced allodynia from the outset. It is important to note that our earlier work 43 examined treatment rather than prevention. In this study, we demonstrate that MDA7 exerts a neuroprotective effect by blunting neuroinflammatory processes that are pivotal for the development of paclitaxelinduced allodynia. We found that MDA7, when given in a time-dependent manner, can (i) prevent the development of paclitaxel-induced mechanical allodynia without compromising the antineoplastic effect of paclitaxel; (ii) prevent increases in levels of glial fibrillary acidic protein (GFAP) in astrocytes and of CD11b in microglia (indicative of neuroinflammatory process activation) that are typically seen within the dorsal horn of paclitaxel-treated rats; (iii) downregulate TLR2 and CB 2 expression in the spinal cord of paclitaxel-treated rats; and (iv) decrease the release of proinflammatory mediators from lipopolysaccharide (LPS)-stimulated primary glial cells in vitro. Because CB 2 agonists prevented paclitaxel-induced neuroinflammation and its downstream consequence, mechanical allodynia, we hypothesize that the CB 2 receptor functions in the immunomodulatory negative-feedback loop and that its early activation can blunt neuroinflammatory responses and mechanical allodynia.
METHODS

Synthesis and Preparation of MDA7
MDA7 was synthesized as described previously 43, 56 and was administered in a vehicle consisting of 25% N-methylpyrrolidone (International Specialty Products, Wayne, NJ), 25% propylene glycol (The Dow Chemical Company, Midland, MI), 10% Cremophor, EL (BASF, Florham Park, NJ), and purified water (Baxter, Deerfield, IL).
Pharmacokinetics of MDA7
The details of preparation of standard curves, extraction, and quantification of MDA7 in rat plasma and brain tissue are described in the Data Supplement (see Supplemental Digital Content 6, http://links.lww.com/AA/A376). 
Animals
Paclitaxel-Induced Allodynia Model
Groups of rats and mice received either vehicle or 1.0 mg/kg paclitaxel daily intraperitoneally (IP) for 4 consecutive days for a final cumulative dose of 4 mg/kg 58 ; the injection volume was 1 mL/kg. Baseline responses to mechanical stimulation of the hindpaw (see below) were established on day 0 and continued for 28 days as described later. The behavioral testing was performed blindly with respect to the drug administration.
Assessment of Mechanical Withdrawal Thresholds
Rats or mice were placed in a compartment with a wire mesh bottom and allowed to acclimate for 30 minutes before testing. Sensory thresholds for the development of allodynia to mechanical stimuli were assessed. Mechanical sensitivity was assessed by using a series of von Frey filaments with logarithmic incremental stiffness (Stoelting Co., Wood Dale, IL), as previously described, 59 and 50% probability paw withdrawal thresholds were calculated with the up-down method. 60 In brief, filaments were applied to the plantar surface of a hindpaw for approximately 6 seconds in an ascending or descending order after a negative or positive withdrawal response, respectively. Six consecutive responses after the first change in response were used to calculate the paw withdrawal threshold (in grams). In rats, when response thresholds occurred outside the range of detection, the paw withdrawal threshold was assigned at 15.00 g for continuous negative responses and at 0.25 g for continuous positive responses. Corresponding values in mice were 2.5 g and 0.02 g, respectively. 61 No rats or mice died during treatment or showed evidence of illness.
Immunohistochemical Analysis
Animals were deeply anesthetized with 2% to 4% isoflurane in oxygen and perfused transcardially with heparinized normal saline (150 mL) followed by 4% formaldehyde (250 mL) and 10% sucrose (200 mL), both in 0.1 M phosphate-buffered saline (PBS), at room temperature. Spinal cords were quickly extruded through a cervical cut by high-pressure injection of ice-cold saline via a needle inserted intrathecally at the level of the cauda equina. The lumbar spinal cords were quickly postfixed in 4% formaldehyde and cryopreserved in 30% sucrose in PBS for 48 to 72 hours at 4°C. The spinal cord tissues were then cut to 25 m in thickness and collected free-floating in 0.1 M PBS. Tissue sections were washed with 0.1% Triton-X 100 in PBS and blocked with donkey or goat serum (according to the secondary antibodies used later) followed by washing with PBS. Primary antibodies (GFAP to label astrocytes: 1:5000, Millipore, Billerica, MA; CD11b [a complement receptor 3 antigen recognized by the OX42 antibody] to label microglial cells: 1:200, Millipore; CB 2 rabbit polyclonal antibody immunoglobulin G [the immunogen is a fusion protein containing the first 32 amino acid residues from rat CB2; catalog number: PA1-746A], 1:500, Affinity BioReagents, Golden, CO; phosphor-p38 MAPK, Cell Signaling, Beverly, MA) were applied to the sections for 2 hours at room temperature and then overnight at 4°C. Sections were washed with PBS and incubated with fluorescein isothiocyanate or Cy3 (as indicated in colocalization study) conjugated secondary antibodies (Jackson ImmunoResearch Laboratories, West Grove, PA) for 2 hours at room temperature. Sections were then rinsed with wash buffer and mounted with SlowFade antifade reagents (Invitrogen, Carlsbad, CA).
Confocal Imaging and Image Analyses
Immunostained tissue sections were imaged using a Zeiss LSM 510 inverted confocal microscope (Carl Zeiss MicroImaging, Inc., Thornwood, NY) with either a 40ϫ or a 25ϫ oil immersion objective. Images were obtained through the full thickness of the tissue section by using fixed serial optical slices along the z-axis, laser power, and detector/ amplifier settings for all treatment conditions to permit quantitatively comparable images for all treatment conditions. For both microglial and astrocytic cell activation, the staining intensities were examined in a standardized area of laminae I to II with 3 to 5 slices examined per animal. The exposure and capture conditions for each channel were adjusted to ensure that images were captured within the dynamic range for all samples. Fluorescence image stacks were quantified for both fluorescence intensity and relative area occupied by labeled objects by using 2 separate methodologies. Negative control sections processed with the secondary antibody alone were used to account for the autofluorescence from the spinal cord itself and nonspecific fluorescence from secondary antibody. First, using Zeiss LSM 3-dimensional software, a specific number of sections were maximally projected. The relative area occupied by the fluorescence objects was then quantified on thresholded projected images. The threshold was set to 2 SDs above the control signals. Second, the images were exported in a tif format into MetaMorph software (Molecular Devices, Downingtown, PA). Multiple representative sections (every 5 optical slices) from each image stack were quantified for total fluorescence intensity and percentage thresholded area after the background fluorescence was subtracted. The Prevention of Paclitaxel-Induced Neuropathy by a CB 2 Agonist stack projections were also quantified for integrated fluorescence and percentage thresholded area. Glial activation is characterized by an increase in the number and complexity of these cells (rounded cell bodies and thicker processes), resulting in an increase in "labeling." The pseudocolored representations of the spatial distributions of fluorescence shown in Figure 3S (see Supplemental Digital Content 3, http://links.lww.com/AA/A373) were used to better define morphological changes. Therefore, an increase in the number of pixels above the threshold value was a measure of glial activation.
Gene Expression Profiling Studies
Total RNA was extracted from spinal cord samples by using mirVana RNA isolation kits (Ambion, Austin, TX), according to the manufacturer's recommendations. The quality of RNA was analyzed using a NanoDrop spectrophotometer (Wilmington, DE) and a microfluidic gel station (Agilent 2100 Bioanalyzer; Agilent Biotechnology, Santa Clara, CA). The wavelength 260/280 ratio was Ͼ1.8 with RNA integrity number Ͼ9. The whole-genome rat gene expression profiling experiments were performed by using 44K-long oligonucleotide microarrays from Agilent Biotechnology. Differentially expressed gene lists were generated from spinal cord samples of each experimental rat by using Agilent software after normalization.
The within-array loess normalization was implemented on the logarithm-2 transformed ratio of cyanine 5 to cyanine 3 signals to diminish the systematic bias that resulted from dye effect and other factors. 62 We conducted the 1-sample t test on the treatment effect for a gene. Explicitly, a nontrivial positive treatment effect indicates up-regulation with MDA7 and paclitaxel treatment, and vice versa. We adopted a false discovery rate, widely used in microarray experiments, to control multiple testing error rates. 63, 64 The false discovery rate is the percentage of false positives among all genes identified as being differentially expressed between 2 treatments. The ␤-uniform mixture model 65 was used to determine the P value threshold based on the false discovery rate.
Quantitative Real-Time Reverse Transcriptase Polymerase Chain Reaction
To determine fold changes in RNA samples, 1.0 g total RNA was reverse transcribed in a 20-L reaction. Maintaining a ratio of 1 g total RNA to 0.4 g random hexamers, random hexamers were added and the mixture was heated at 70°C for 10 minutes. The tubes were then incubated at room temperature for 10 minutes, and the following components were added: 1ϫ Superscript II Reverse Transcriptase (RT) Buffer (Invitrogen), 10 mM DTT (Invitrogen), 0.5 mM dNTPs (ISC Bioexpress, Kaysville, UT), 20 U RNase Inhibitor (Ambion), and 200 U Superscript II RT (Invitrogen). The reaction was incubated for 10 minutes at room temperature and then held at 37°C for 1 hour. The reaction was then incubated at 42°C for 1.5 hours followed by 50°C for 30 minutes. RT polymerase chain reaction (PCR) was performed on the ABI Prism 7900 using the Assays-on-
(Rn00696209_m1), Akr7a3 (Rn00566256_m1), and the Rat GAPD (4352338E). Vic-labeled Pre-Developed Assay Reagent (Applied Biosystems, Foster City, CA) was used without multiplexing using a 15-L final reaction volume containing 1ϫ TaqMan Universal PCR Master Mix (Applied Biosystems) and 1ϫ Assay-on-Demand. A total of 2.5 ng/well cDNA was amplified with the following cycling conditions: 10 minutes at 95°C followed by 50 cycles of 95°C for 15 seconds and 60°C for 1 minute. The 7900 Sequence Detection System 2.3 software automatically determined fold-change for each sample using the ⌬⌬Ct method with 95% confidence.
Cell Cultures
Primary Astroglial Cell Culture Astrocyte-enriched cultures were prepared from cerebral cortices of 2-or 3-day-old Sprague-Dawley rats with few modifications to the method previously described. 66 In brief, rats were decapitated and cerebral cortices immediately dissected out. After meninges and blood vessels were removed, the tissues were minced and washed in PBS and then incubated for 30 minutes at 37°C in 0.25% trypsin-EDTA (Sigma, St. Louis, MO). Cells were then mechanically triturated through a glass pipette and filtered through a 70-m nylon mesh in the presence of 10% fetal bovine serum (FBS) in Dulbecco's modified Eagle medium (DMEM)/ F12 (Mediatech, Manassas, VA) and 15,000 IU/mL DNase I (Sigma). After centrifugation (500g), cells in 90% DMEM, 10% FBS, 20 U/mL penicillin, and 20 g/mL streptomycin were seeded in plastic Petri dishes or cell culture plates (BD Falcon, Franklin Lakes, NJ) at 1.25 ϫ 10 5 cells/cm 2 . Cells were maintained in a humidified atmosphere of 90% air/10% CO 2 . The medium was changed once a week, and cells were used after 14 to 19 days in vitro.
CHO-CB 2 and HEK-293-TLR Cell Cultures
The rat (r)CB 2 -transfected or human (h)CB 2 -transfected Chinese hamster ovary (CHO) cells were cultured in HAM-F12 medium (Mediatech) containing 10% FBS (Sigma), 100 IU/mL penicillin, 100 g/mL streptomycin, and 400 g/mL G418. The TLR2 or TLR4 transfected human embryonic kidney (HEK) cells were purchased from InvivoGen (San Diego, CA) and cultured in DMEM containing 10% FBS, 100 IU/mL penicillin, 100 g/mL streptomycin, and 100 g/mL each of Normocin and HEK-Blue selection (antibiotics for maintenance of the transfected cells, both from InvivoGen), according to the manufacturer's instructions.
Western Blotting
Western Blotting in Lumbar Spinal Cord Tissue
Groups of rats were injected with paclitaxel at 1 mg/kg for 4 days, or paclitaxel for 4 days plus 15 mg/kg MDA7 (15 minutes before paclitaxel) for 4 or 14 days. Animals were deeply anesthetized with 2% to 4% isoflurane in oxygen and perfused transcardially with normal saline (150 mL). Spinal cords were quickly extruded through the cervical cut by high-pressure injection of ice-cold saline via a needle inserted intrathecally at the level of the cauda equina. The lumbosacral enlargement was excised, and if not studied immediately afterward, was frozen on dry ice and stored at Ϫ80°C until assayed. Lumbar spinal tissues were homogenized and sonicated in buffer 1.0% Nonidet P-40, 20 mM HEPES (pH 7.5), 150 mM NaCl, 10% glycerol, 60 mM octyl ␤-glucoside, 10 mM NaF, 1.0 mM Na 3 VO 4 , 2.5 mM nitrophenylphosphate, 1 mM phenylmethylsulfonyl fluoride, 0.7 g/mL pepstatin, and a protease inhibitor cocktail tablet (Roche, Mannheim, Germany), and centrifuged at 12,000 rpm at 4°C for 15 minutes. The supernatants (lysate) were collected. From the lysate, total protein was taken and dissolved in 2ϫ Laemmli buffer. The samples were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and then transferred onto nitrocellulose membranes (Whatman Inc., Florham Park, NJ). Antibodies against CB 2 (1:500; Affinity BioReagents), extracellular signal-regulated kinase (ERK)1/2 and phosphorylated-ERK1/2 (1:1500; Cell Signaling), IkB␣ and phosphorylated IkB␣ (1:1000; Cell Signaling), TLR2 (1:500; Imegenex, San Diego, CA) and TLR4 (1:500; Imegenex), and ␤-actin (1:1000; Cell Signaling) were used as the primary antibodies.
Western Blotting in CHO-CB 2 and HEK-293-TLR Cell Cultures
Cells were treated with dimethyl sulfoxide (DMSO) (vehicle) and 0.1 M paclitaxel (15 minutes) with or without 1 and 10 M MDA7 (1 hour before paclitaxel). Antibodies to ERK1/2 and phosphorylated-ERK1/2 (1:1500; Cell Signaling) were used as the primary antibodies. Cells were lysed and sonicated in buffer (1.0% Nonidet P-40), 20 mM HEPES (pH 7.5), 150 mM NaCl, 10% glycerol, 60 mM octyl ␤-glucoside, 10 mM NaF, 1.0 mM Na 3 VO 4 , 2.5 mM nitrophenylphosphate, 1 mM phenylmethylsulfonyl fluoride, 0.7 g/mL pepstatin, and a protease inhibitor cocktail tablet (Roche) and centrifuged at 12,000 rpm at 4°C for 15 minutes. The supernatants (lysate) were collected. From the lysate, total protein was taken and dissolved in 2ϫ Laemmli buffer. The samples were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and then transferred onto nitrocellulose membranes (Whatman Inc.). ␤-Actin was used as loading control. Band analysis (quantification) was conducted using Alpha Innotech FluorChem FC12 software (San Leandro, CA).
Measurement of Cytokine Production in the Cultured Astroglial Cells (Enzyme-Linked Immunosorbent Assay Analysis)
The primary astroglial cultured cells were treated with 5 M DMSO (solvent), 1.0 g/mL LPS, 67 and 100 g/mL zymosan with or without 10 M MDA7. Cell culture supernatants were collected 24 hours after treatment. IL-1␤ and TNF-␣ were quantified by using commercial enzymelinked immunosorbent assay kits from R&D Systems (Minneapolis, MN) with a sensitivity of Ͻ5 pg/mL. Experiments were performed in triplicate.
Flow Cytometric Analysis
The quantification of an apoptotic response was performed using an LSR Flow Cytometer 
Statistical Analysis
For behavioral data in rats, linear mixed models 68 with treatment and day effects with repeated measures over days were used to assess whether MDA7 significantly prevented paclitaxel-induced allodynia. In the mice study, a linear mixed model with a random intercept effect was used to account for the dependent measurements over time. This model includes the genotype, time, and interaction between genotype and time as the fixed effect. This model allows assessing the baseline effect, the time effect, and the difference between the genotypes in terms of the change over time. The quadratic term of time is included if the change of the measurements over time is nonlinear. We used a 2-way analysis of variance model to compare the baseline measurements between the 2 mice genotypes (at day 0). Immunohistochemistry and immunoblot data were analyzed using the t test or 2-way analysis of variance followed by post hoc Student-Newman-Keuls test. All data are expressed as mean Ϯ SEM. P Ͻ 0.05 was considered statistically significant.
RESULTS
Administration of MDA7 Effectively Prevents Paclitaxel-Induced Allodynia Through the CB2 Receptor System
Tactile allodynia (pain induced by tactile stimulation that is not normally painful) is a clinically important component of neuropathic pain and is frequently considered as a primary end point in neuropathic pain models. To develop a rat model for studying mechanical allodynia after paclitaxel treatment, we administered 1 mg/kg paclitaxel IP in rats for 4 consecutive days. 43, 58 This resulted in the development of tactile allodynia in all of the rats, as shown by a reduction in paw withdrawal threshold to mechanical stimulation with von Frey filaments, from 14.4 Ϯ 0.6 g before the start of paclitaxel administration to 2.1 Ϯ 0.3 g by day 8 after administration. This paclitaxel-induced allodynia persisted throughout the 28-day study period (Fig. 1A) .
To determine whether MDA7 could prevent paclitaxelinduced allodynia and exert a neuroprotective effect, we administered 15 mg/kg MDA7 IP 15 minutes before each paclitaxel dose for 4 days and then continued daily MDA7 administration for another 10 days (total period of MDA7 treatment was 14 consecutive days). This schedule of MDA7 treatment prevented paclitaxel-induced allodynia in all rats; the protective effects lasted throughout the study period (4 days during and 24 days after paclitaxel administration) (Fig. 1) . In contrast, MDA7 (15 mg/kg IP) given 15 minutes before the paclitaxel administration for only the first 4 days of paclitaxel administration delayed but did not prevent paclitaxel-induced allodynia. This result suggests that MDA7 treatment does not directly interfere with paclitaxel action and that the downstream effects of paclitaxel treatment can still be elicited over a window of time after discontinuation of paclitaxel treatment.
Because MDA7 was designed as a CB 2 agonist, it was important to determine whether the observed protective effects of MDA7 were directly mediated through CB 2 receptor activation. We therefore administered 5 mg/kg IP of AM630, a CB 2 antagonist, to rats before MDA7 (15 mg/kg IP) administration. This abolished the protective effects of MDA7 (Fig. 1) . To further explore whether the neuroprotective effect of MDA7 directly involved CB 2 receptor activation, we performed parallel studies in mice lacking the CB 2 receptor. Interestingly, CB 2 Ϫ/Ϫ mice were inherently more sensitive (P ϭ 0.005) to tactile stimulation than CB 2 ϩ/ϩ mice at the outset of the experiment and had a more rapid onset (P ϭ 0.019) of allodynia after paclitaxel administration, suggesting that the CB 2 Ϫ/Ϫ mice exhibit a presensitization syndrome Figure 1 . A, Prevention of paclitaxel-induced mechanical allodynia in rats (n ϭ 6 in all groups except vehicle control, n ϭ 4). Treatment with paclitaxel ϩ MDA7 for 14 days resulted in significant differences (P Ͻ 0.001) from paclitaxel alone on days 5 to 28, whereas treatment with paclitaxel ϩ MDA7 for only 4 days resulted in significant differences (P Ͻ 0.01) on days 5 to 12 only. B, Confocal images of CD11b immunoreactivity in various groups of rats. Top, immunofluorescence staining intensity patterns of each section. C, Analysis of CD11b immunofluorescence intensity by Metamorph (5-6 sections) showed that the paclitaxel ϩ MDA7 14 days group had significantly less immunofluorescence integrated intensity than did the paclitaxel only and paclitaxel ϩ MDA7 4 days groups (D). Confocal images of glial fibrillary acidic protein (GFAP) immunoreactivity in various groups of rats. Top, immunofluorescence staining intensity patterns of each section. E, Analysis of GFAP immunofluorescence integrated intensity by Metamorph (2-3 sections) showed that the paclitaxel ϩ MDA7 14 days group had significantly less immunofluorescence intensity than the paclitaxel only and paclitaxel ϩ MDA7 4 days groups had. Scale bar ϭ 50 m.
and are prone to more severe allodynia. Of note, MDA7 was shown to protect CB 2 ϩ/ϩ mice but not CB 2 Ϫ/Ϫ mice from paclitaxel-induced allodynia (Fig. 2) . These parallel studies in rats and mice strongly support the notion that the protective effect of MDA7 was mediated through the CB 2 receptor.
Pharmacokinetics of MDA7
An important observation from the above experiment was that, whereas a 4-day MDA7 treatment only delayed (but did not prevent) paclitaxel-induced allodynia, a 14-day course provided a neuroprotective effect that lasted long after MDA7 administration was discontinued. There could be 2 explanations for this observation: the therapeutic concentrations of MDA7 may require Ͼ4 days; or, there is a window of therapeutic opportunity for MDA7's protective effect. To better understand this phenomenon, we determined the pharmacokinetics of MDA7 in rats in both the plasma and the CNS. As illustrated in Figure 2S (see Supplemental Digital Content 2, http://links.lww.com/AA/A372), IV administration of MDA7 achieved a CNS concentration (C max of 15 g/g) that was 3 times larger than that simultaneously measured in plasma; however, the MDA7 concentration decreased to Ͻ0.1 g/mL within 4 hours.
MDA7 Effectively Ameliorates the Activation of Spinal Astrocyte and Microglia Induced by Paclitaxel
Because prior studies showed an association between the development of mechanical allodynia and glial cell activation, 69, 70 we considered the possibility that MDA7's preventive effect on paclitaxel-induced allodynia in rats was mediated through modulation of glial activation. Increased expression of specific markers such as CD11b and GFAP has been associated with activation of microglia 71 and astrocytes, 72 respectively. We therefore examined the impact of MDA7 on paclitaxel-induced microglial and astrocyte activation by comparing the levels of immunofluorescence staining for CD11b and GFAP in the dorsal horn laminae I and II of the lumbar spinal cord of rats in the various treatment groups tested shown in Figure 1 (on day 28). Glial activation is characterized by an increase in the number and complexity of these cells (rounded cell bodies and thicker processes), resulting in an increase in both the number of labeled cells and the total integrated intensity of the labeled cells (Fig. 3S , see Supplemental Digital Content 3, http://links.lww.com/AA/A373). When rat lumbar spinal cords were examined on day 28, profoundly increased CD11b and GFAP immunoreactivity, enlarged cell mass, and increased cell complexity were noted in the microglia (Fig. 1, B and C) and astrocytes (Fig. 1, D and E) of paclitaxel-treated rats. These changes were strongly attenuated in paclitaxel-treated rats receiving 14 days of MDA7 treatment (Fig. 1 , B-E) and correlated well with the effect of MDA7 in preventing mechanical allodynia in the rats (Fig. 1A) .
We also found that CB 2 expression was enhanced with paclitaxel administration (F (1,10) ϭ 13.69, n ϭ 12, P Ͻ 0.01 versus control group) and that this expression is colocalized with the reactive astrocytes. Administration of paclitaxel and MDA7 for 14 days resulted in reduced CB 2 expression present at day 28 ( Fig. 3; F (1,10) ϭ 10.65, n ϭ 12, P Ͻ 0.01 versus paclitaxel group). Interestingly, the microglial activation marker CD11b was significantly increased (P Ͻ 0.001) in paclitaxel-treated rats after MDA7 treatment for only 4 days compared with paclitaxel treatment only (Fig. 1, B and C) . Conversely, the astrocytic activation marker GFAP showed the opposite pattern when measured at day 28 ( Fig. 1, D and E) .
Molecular Pathway of Paclitaxel-Induced Allodynia and Its Modulation by MDA7
To gain insight into the molecular pathways involved in the development of paclitaxel-induced allodynia and its prevention by MDA7, we performed a second independent experiment similar to that described in Figure 1 except that the animals were euthanized on day 15 (1 day after the last MDA7 dose). Total RNA was extracted from spinal cord samples of rats treated with paclitaxel (1 mg/kg IP daily for 4 days) or paclitaxel (1 mg/kg IP daily for 4 days) ϩ MDA7 (15 mg/kg IP daily for 14 days) (n ϭ 6 in each group). Whole-genome rat gene expression profiling experiments were performed by using rat 44K-long Agilent Biotechnology oligonucleotide microarrays. Although some variation was observed between similarly treated rats (Fig. 4A) , we detected 384 genes that had significantly differential expression between paclitaxel-treated rats that did or did not receive MDA7, with P Ͻ 1.74 ϫ 10 Ϫ4 based on the false discovery rate cutoff of 0.005 (Fig. 4A ) (see Table 1S in Supplemental Digital Content 6, http://links.lww.com/AA/A376). There were 96 genes differentially decreased in expression and 288 genes differentially increased in expression between the 2 groups. Microarray expression data from all spinal cord samples were validated at the protein level by Western blotting (Fig.  4, C-H) or at the RNA level by quantitative (q)RT-PCR (Fig.  4B) based on an examination of 7 gene products selected for their known involvement in inflammatory pathways, including: (i) protein O-fucosyltransferase 2 (Pofut2_predicted), an essential component of the Notch signaling pathway, 73, 74 which is involved in neuronal and glial differentiation and modulation of the expression of proinflammatory cytokines 75, 76 : 1.9-fold difference; (ii) Cyp26b1, a regulator of retinoic acid oxidation associated with human CNS development 77 : 1.8-fold difference; (iii) IL-1␤: 1.2-fold difference; (iv) TNF-␣: 1.2-fold difference; (v) TLR2: 1.3-fold difference; (vi) IB␣: 1.3-fold difference; and (vii) ERK1 and ERK2, activated in the microglia within 1 to 3 days and in astrocytes after 3 weeks in the neuropathic spinal nerve ligation model: 1.22-and 1.04-fold changes, respectively. These qRT-PCR results yielded the same trends as those obtained from the microarray analyses. Moreover, at the protein level, paclitaxel treatment alone was associated with upregulated TLR2 expression (F (1, 8) ϭ 12.1, n ϭ 10, P Ͻ 0.05) and increased phosphorylation of ERK1/2 (F (1, 8) ϭ 7.9, n ϭ 10, P Ͻ 0.05) and IB␣ (F (1, 8) ϭ 11.1, n ϭ 10, P Ͻ 0.05) in the rat spinal cord (Fig. 4, C-H) . MDA7 treatment for 14 days significantly attenuated the upsurge of phosphorylation of ERK1/2 (Fig. 4, C and D) (F (1,8) ϭ 8.36 , n ϭ 10, P Ͻ 0.05) and IB␣ (Fig. 4, E and F) (F (1,8) ϭ 8.35 , n ϭ 10, P Ͻ 0.05), and down-regulated TLR2 expression (Fig. 4, G  and H) (F (1,8) ϭ 8.11 , n ϭ 10, P Ͻ 0.05) but did not affect TLR4 (Fig. 4, G and H) (F (1,6) ϭ 0.25, n ϭ 8, P Ͼ 0.05) expression in the lumbar spinal cord of the rats with paclitaxel treatment. Figure 3 . A, Cannabinoid type 2 (CB 2 ) staining and localization in the lumbar spinal cord dorsal horn laminae I and II. Representative confocal images of CB 2 (green) and glial fibrillary acidic protein (GFAP) (red). The coregionalization of CB 2 and GFAP in astrocytes is shown in yellow. No significant CB 2 expression was observed in the control group, but marked CB 2 expression was observed in the paclitaxel group. CB 2 expression was markedly decreased with MDA7 treatment for 14 days. Scale bar ϭ 50 m. B and C, Paclitaxel treatment significantly increased the CB 2 expression in the lumbar spinal cord, and treatment with MDA7 for 14 days significantly attenuated this upregulated CB 2 expression in the rats treated with paclitaxel. Figure 4 . A, Heatmap of the expression intensities in the individual samples of the most significant 384 genes detected on the basis of the threshold of false discovery rate cutoff of 0.005. Hierarchical clustering based on the Pearson correlation coefficient was conducted among the 384 genes. B, Quantitative real-time reverse transcriptase polymerase chain reaction analysis of total RNA performed in triplicates isolated from all 12 spinal cord samples used in a microarray study (6 from paclitaxel-treated rats and 6 from paclitaxel ϩ MDA7 14-day treated rats). Data were normalized relative to Gapdh and expressed as fold change relative to paclitaxel treatment without MDA7. The RNA fold change matches the trend seen in microarray data. Further, Western blotting analysis revealed that MDA7 treatment for 14 days significantly attenuated the upsurge of phosphorylation of extracellular signal-regulated kinase (ERK)1/2 (C, D) and IB␣ (E, F), and down-regulated toll-like receptor 2 (TLR2) expression (G, H) but did not affect TLR4 (G, H) expression in the spinal cord of the rats with paclitaxel treatment. *P Ͻ 0.05. SC ϭ spinal cord; Taxol ϭ paclitaxel; IL ϭ interleukin; TNF ϭ tumor necrosis factor.
MDA7 Attenuates Proinflammatory Cytokine Secretion Induced by LPS and Zymosan via Suppression of ERK1/2 Signaling in Primary Cultured Astroglial Cells
To better understand the basis for MDA7's interference with paclitaxel-induced allodynia, we examined the impact of MDA7 treatment on proinflammatory cytokine secretion by cultured astroglial cells that express TLRs. 78 LPS (a ligand for TLR4) 79 and zymosan (a ligand for TLR2) 80 elicit the secretion of proinflammatory cytokines in this model system. Prior studies indicated the involvement of TLR4 signaling in both paclitaxel-and LPS-induced signaling pathways. 81 LPS has also been shown to increase CB 2 receptor levels. 82 As shown in Figure 5 , A and B, secreted levels of IL-1␤ and TNF-␣ were significantly increased in primary rat astroglial cell cultures after 1.0 g/mL LPS or 100 g/mL zymosan stimulation, and these increases were blunted by MDA7 treatment. Pretreatment with MDA7 significantly inhibited LPS-induced increases in IL-1␤ ( Fig.  5A; F (1,8) ϭ 28.38, n ϭ 10, P Ͻ 0.001) and TNF-␣ secretion ( Fig. 5B; F (1,5) ϭ 64.41, n ϭ 7, P Ͻ 0.001). Similarly, it also suppressed zymosan-induced increases in IL-1␤ ( Fig. 5A ; F (1,6) ϭ 8.07, n ϭ 8, P Ͻ 0.05) and TNF-␣ secretion ( Fig. 5B;  F (1,4) ϭ 506.03, n ϭ 6, P Ͻ 0.001). Treatment of these primary astroglial cultures with 0.1 M paclitaxel was associated with increased TLR2 (but not TLR4) gene expression ( Fig. 5C; F (1,4) ϭ 11.08, n ϭ 6, P Ͻ 0.05), but paclitaxel alone failed to induce IL-1␤ and TNF-␣ production in this in vitro model (data not shown), suggesting that paclitaxel treatment itself may not cause TLR2 or TLR4 activation similar to that induced by LPS or zymosan. Of interest, the increase in TLR2 gene expression associated with paclitaxel treatment was suppressed by MDA7 treatment ( Fig. 5C; F (1,4) ϭ 14.00, n ϭ 6, P Ͻ 0.05), suggesting that MDA7 can impact an early component of paclitaxelinduced signaling pathways.
MDA7 Suppresses Paclitaxel-Induced ERK1/2 Activation in CHO-CB 2 and HEK-TLR2/4 Cells
We determined the effect of MDA7 on ERK phosphorylation in hCB 2 -or rCB 2 -transfected CHO cells and in TLR2-or TLR4-transfected HEK-293 cells after paclitaxel treatment. 83 Figure 4S (see Supplemental Digital Content 4, http://links.lww.com/AA/A374) shows that TLR-transfected HEK-293 cells express CB 2 receptors. We noted that both endogenous ERK1/2 phosphorylation (in CB 2 -transfected cells) and paclitaxel-induced ERK1/2 phosphorylation were suppressed by MDA7 (Fig. 6 ) in a dose-dependent manner. Treatment with MDA7 significantly suppressed phosphorylation of ERK1/2 in TLR2-transfected (F (1,4) ϭ 8.56, P Ͻ 0.05) or TLR4-transfected (F (1,4) ϭ 19.97, P ϭ 0.01) HEK-293 cells compared with paclitaxel-treated cells. Although paclitaxel has been shown to induce ERK1/2 phosphorylation, 84 our data show that the effect of paclitaxel on ERK1/2 phosphorylation did not differ significantly from controls in TLR2-transfected (F (1, 4) ϭ 0.33, n ϭ 6, P ϭ 0.32) or in TLR4-transfected (F (1,4) ϭ 5.15, n ϭ 6, P ϭ 0.08) HEK-293 cells (Fig. 7) . This MDA7-induced effect can be blocked by a CB 2 antagonist (AM630), as demonstrated in the TLRtransfected HEK-293 cells and CB 2 -CHO cells shown in Figure 5S (see Supplemental Digital Content 5, http://links.lww.com/AA/A375). Recently, it has been shown that AM630 behaves as a protean ligand at the hCB 2 receptor. 85 Depending on the cell context, a protean agonist ligand can be an agonist, neutral antagonist, or inverse agonist at the same receptor type. Therefore, the effect of AM630 on the levels of pERK in both CHO-CB 2 cells and HEK-TLR2 cells is not unexpected (Fig. 5S, If MDA7 is to be indicated for the prevention of peripheral neuropathy in the chemotherapy setting, it is important that MDA7 not compromise the cytotoxic effects of paclitaxel on tumor cells. To address this issue, we determined the effect of MDA7 on paclitaxel-induced cell death in various human cancer cell lines, including MCF7 breast adenocarcinoma, H1299 lung cancer, and Jurkat leukemia cells. The addition of MDA7 to paclitaxel during a 24-hour (data not shown) or a 48-hour treatment did not compromise the ability of paclitaxel to induce a necrotic (PI uptake) or apoptotic (Annexin staining) reaction (Fig. 8) . In fact, MDA7 itself increased cell death in MCF7 cells above control levels. These results are consistent with prior studies demonstrating antiproliferative effects of CB 2 agonists on a wide spectrum of tumor cells 86, 87 and further supports MDA7's potential indication for preventing mechanical allodynia in the chemotherapy setting.
DISCUSSION
Our results reveal a promising potential role for the CB 2 agonist MDA7 in preventing paclitaxel-induced mechanical allodynia. Our preclinical data indicate that MDA7 prevented paclitaxel-induced allodynia in rats and in CB 2 ϩ/ϩ mice, perhaps by upregulating an immunomodulatory negative-feedback loop early during a paclitaxelinduced neuroinflammatory reaction. The in vivo studies demonstrated that paclitaxel treatment resulted in activation and expansion of microglia and astrocytes in the spinal cord, a process that was blunted by MDA7 treatment. Similarly, concomitant treatment of paclitaxel-treated animals with MDA7 was associated with decreased expression of genes involved with the neuroinflammatory response.
The in vitro studies further demonstrated that MDA7 treatment could attenuate activation of early signaling pathways associated with the neuroinflammatory pathway by interfering with paclitaxel-induced TLR2 upregulation and ERK1/2 phosphorylation, and this was associated with decreased secretion of proinflammatory cytokines (e.g., IL-1␤ and TNF-␣). The finding that paclitaxel treatment was associated with increased CB 2 expression in the dorsal horn laminae I and II lumbar spinal cord in paclitaxel-treated rats (Fig. 3 ), yet treatment with the CB 2 agonist MDA7 prevented the development of mechanical allodynia, raises the possibility that the CB 2 receptor acts as a negative-feedback regulator and its early activation by MDA7 can serve to limit the extent of the neuroinflammatory response and the subsequent development of allodynia. Moreover, by blunting the development of paclitaxel-induced microgliosis in the spinal cord, early MDA7 treatment may result in reduced sensitization for subsequent paclitaxel courses. Administering 15 mg/kg IP of MDA7 15 minutes before administering paclitaxel for 4 days and then continuing the MDA7 for another 10 days (total period of MDA7 administration was 14 consecutive days) prevented paclitaxelinduced allodynia in rats and in CB 2 ϩ/ϩ mice but not in CB 2 Ϫ/Ϫ mice. These findings suggest that (i) the presence of the CB 2 receptor is critical for the neuroprotective activity of MDA7, and (ii) MDA7 itself does not directly interfere with paclitaxel activity. Administering 15 mg/kg IP of MDA7 for only the first 4 days of paclitaxel administration delayed but did not prevent paclitaxel-induced allodynia. This suggests that (i) there is a window of preventive opportunity whereby CB 2 agonists have maximal activity, and (ii) the upstream signal initiating paclitaxel-induced allodynia is transitory in nature and that continued effective concentrations of MDA7 need to be present in the CNS during this interval to effectively block this neuroinflammatory-initiating signal.
Our in vivo analyses showed that the level of microglial activation marker CD11b (measured on day 28) was significantly higher (P Ͻ 0.001) after MDA7 treatment for 4 days than it was after paclitaxel treatment alone (Fig. 1, B  and C) ; however, the astrocytic activation marker GFAP showed an opposite pattern (Fig. 1, D and E) . This suggests that the microglia are involved in the initiating phase of behavioral hypersensitivity, whereas astrocytes are involved in the maintenance phase. 88 -90 This notion is supported by observations of others that microglial cells begin to retract their fine ramifications, enlarge, and enter mitosis within 24 hours after axotomy, later followed by astrocyte activation. 88 Our results are consistent with previously published reports in which a similar dosing regimen of paclitaxel resulted in mechanical allodynia 43, 58, 91, 92 and microglial activation. 93 Zheng et al., 94 however, failed to demonstrate microglial activation after paclitaxel administration perhaps because of measuring a different end point of markers or the use of a high threshold for their measurements.
The present studies provide some insight into the mechanism by which this CB 2 agonist, MDA7, blunts the paclitaxel-induced neuroinflammatory response associated with mechanical allodynia. Signaling via TLRs is thought to mediate the expression of a wide array of genes involved in inflammatory and immune responses. 95 Although TLRs seem to be differentially upregulated in stimulated microglia in different stimulatory settings, 96 TLR2 has been reported to be involved in glial cell activation associated with models of neuropathic pain. 21, 97 The finding that MDA7 has a relatively short half-life suggests that its protective mechanism might involve an inhibition of a TLR activation pathway (e.g., binding to TLR and preventing TLR dimerization necessary for activation) rather than a competitive pathway (which might require chronic administration). Both spinal cord microglia activation and proinflammatory gene expression in the spinal cord (such as TNF-␣ and IL-1␤) induced by nerve injury were reduced in TLR2 knockout mice. 97 Our finding of relatively reduced paclitaxel-induced TLR2 expression levels along with decreased ERK1/2 phosphorylation in MDA7-treated animals and decreased secretion of inflammatory cytokines in MDA7-treated cells in vitro suggest that MDA7 treatment modulates early events in the paclitaxel-induced neuroinflammatory response underlying the development of mechanical allodynia.
ERK regulates a wide spectrum of cell functions and has been shown to have an important role in tissue and nerve injury 98, 99 and pain sensitization. 100 After nerve injury, ERK1/2 is differentially activated (phosphorylated) in spinal glial cells. 101 Moreover, inhibition of ERK pathways has been shown to attenuate TNF production 102 and mechanical allodynia in different animal models. 99 However, current ERK inhibitors have poor CNS penetration characteristics and have not proven beneficial in preclinical trials because of their toxicity and limited efficacy. 103 Anandamide has been shown to modulate ERK1/2 activation within the CNS immune system, to reduce the extent of the inflammatory response, and to limit neurodegenerative immune reactions. 104 Our data indicate that MDA7 treatment can reduce phosphorylated ERK1/2 signaling at an early stage in the neuroinflammatory process and potentially blunt downstream pathways that generate allodynia.
Taken together, our data suggest that paclitaxel treatment initiates a neuroinflammatory process in the spinal cord characterized by increased glial activation, involving increased expression of TLR2 and CB 2 receptors, and the release of proinflammatory cytokines known to directly damage sensory neurons, resulting in mechanical allodynia. These results are consistent with the findings that TLR pathway activation is a key initiating component of the neuroinflammatory process, 105 and mice with TLR2-deficient microglia have reduced neuroinflammatory responses. 106 Activation of TLRs are also reported to lead to ERK1/2 phosphorylation, 107 and TLR-induced MAPKs have been found to be crucial for cytokine production by innate immune cells. 108 Importantly, we have also shown that this process could be prevented by the administration of a CB 2 agonist (MDA7) when given proximal to paclitaxel administration. Moreover, gene expression analyses suggested MDA7 administration was associated with blunted paclitaxel-induced increases in TLR2 and cytokine(s) expression.
The present study focuses on the spinal mechanism underlying paclitaxel-induced mechanical allodynia in the dorsal horn, the primary site for the integration of nociceptive information. 109 There is evidence, however, for the association between paclitaxel-induced allodynia and peripheral sensory neuron mitochondrial dysfunction. 110 Although acetyl l-carnitine, a naturally occurring amino acid derivative, has been shown to ameliorate paclitaxel-induced allodynia and decrease the incidence of swollen and vacuolated mitochondria in C fibers (but not in A fibers) in rodents, 111 it did not show superiority to placebo when used for treatment of human immunodeficiency virus-associated sensory neuropathy in randomized controlled clinical trials. 10 Superoxide produced from mitochondrial oxidative phosphorylation is considered the major source of reactive oxygen species in neurons, and global inhibition of reactive oxygen species has been shown to ameliorate paclitaxel-induced mechanical allodynia, whereas selective inhibition of superoxide radicals was ineffective. 112 The present study has several clinical implications. The use of high paclitaxel doses and higher intensity schedules is associated with higher response rates and longer response durations in cancer patients. 113 However, with higher cumulative doses and more intense treatment schedules, debilitating neurotoxicity becomes the dose-limiting toxicity in up to 71% of patients. 3, 5 Moreover, the risk of developing neuropathy after treatment with paclitaxel is larger in patients who have preexisting conditions that may cause neuropathy (e.g., diabetes) or who have been treated previously with other neurotoxic chemotherapeutic drugs such as cisplatin and vincristine. 114 The finding that a CB 2 agonist such as MDA7 can prevent the development of paclitaxel-induced mechanical allodynia is a significant advance for several reasons. First, the use of this CB 2 agonist may allow the use of higher doses of chemotherapy or higher intensity treatment durations when one considers a potential therapeutic window for intervention. Second, understanding the mechanistic basis by which CB 2 agonists upregulate the negative-feedback loop of the neuroinflammatory process and understanding how MDA7 can prevent chemotherapy-induced mechanical allodynia could provide the foundation for the development of new, targeted neuroprotective strategies in several neurologic disorders associated with an excessive neuroinflammatory process.
